title: Treatment of primary systemic necrotizing vasculitides: the role of biotherapies.
abstract: Treatments of systemic necrotizing vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities to prolong survival and prevent relapses, while decreasing the severity and number of side effects. The French Vasculitis Study Group, the European Vasculitis Study Group or the Vasculitis Clinical Research Consortium organized most of the prospective clinical trials that have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include: immunomodulating methods (e.g. plasma exchanges), products (e.g. intravenous immunoglobulins) or, more recently, new agents called biotherapies. Some of the latter, mainly anti-CD20 monoclonal antibodies, have achieved promising effects and are now being evaluated in prospective trials.
authors.affiliation: Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris, René-Descartes, 27, rue du Faubourg Saint-Jacques, 75679, Paris Cedex 14, France. loic.guillevin@cch.aphp.fr.
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods; D001808:Blood Vessels / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009336:Necrosis; D010951:Plasma Exchange; D012720:Severity of Illness Index; D056647:Systemic Vasculitis / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha
references.citation: N Engl J Med. 2005 Jan 27;352(4):351-61
references.pmid: 15673801
references.citation: Medicine (Baltimore). 2011 Jan;90(1):19-27
references.pmid: 21200183
references.citation: Rheumatology (Oxford). 2014 Mar;53(3):532-9
references.pmid: 24282319
references.citation: Ann Rheum Dis. 1994 May;53(5):334-7
references.pmid: 7912504
references.citation: Arthritis Rheum. 2011 Jan;63(1):257-66
references.pmid: 20862686
references.citation: N Engl J Med. 2012 Jul 19;367(3):214-23
references.pmid: 22808956
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):619-22
references.pmid: 23477710
references.citation: N Engl J Med. 2010 Jul 15;363(3):211-20
references.pmid: 20647198
references.citation: QJM. 2000 Jul;93(7):433-9
references.pmid: 10874052
references.citation: Arthritis Rheum. 2010 Apr;62(4):1186-97
references.pmid: 20131268
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):530-2
references.pmid: 23477713
references.citation: Nephron Clin Pract. 2006;102(1):c35-42
references.pmid: 16174989
references.citation: N Engl J Med. 2013 Aug 1;369(5):417-27
references.pmid: 23902481
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):643-50
references.pmid: 23474045
references.citation: QJM. 1994 Nov;87(11):671-8
references.pmid: 7820541
references.citation: Arthritis Rheum. 2001 Mar;44(3):666-75
references.pmid: 11263782
references.citation: Ann Intern Med. 2009 May 19;150(10):670-80
references.pmid: 19451574
references.citation: N Engl J Med. 2003 Jul 3;349(1):36-44
references.pmid: 12840090
references.citation: N Engl J Med. 2008 Dec 25;359(26):2790-803
references.pmid: 19109574
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):575-6
references.pmid: 23453209
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):589-91
references.pmid: 23490642
references.citation: Arthritis Rheum. 1997 Dec;40(12):2187-98
references.pmid: 9416856
references.citation: JAMA. 2010 Dec 1;304(21):2381-8
references.pmid: 21060104
references.citation: Arthritis Rheum. 2005 Aug;52(8):2461-9
references.pmid: 16052573
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):532-4
references.pmid: 23490639
references.citation: Arthritis Rheum. 2008 Feb;58(2):586-94
references.pmid: 18240234
references.citation: Arthritis Rheum. 2013 Jan;65(1):270-81
references.pmid: 23044708
references.citation: Medicine (Baltimore). 1996 Jan;75(1):17-28
references.pmid: 8569467
references.citation: J Autoimmun. 1993 Apr;6(2):207-19
references.pmid: 8499059
references.citation: Kidney Int. 1991 Oct;40(4):757-63
references.pmid: 1745027
references.citation: Arthritis Rheum. 2012 Feb;64(2):542-8
references.pmid: 21953279
references.citation: Arthritis Rheum. 2010 Feb;62(2):616-26
references.pmid: 20112401
references.citation: Ann Rheum Dis. 2008 Sep;67(9):1343-6
references.pmid: 18445626
references.citation: Arthritis Rheum. 2008 Jan;58(1):308-17
references.pmid: 18163506
references.citation: Br J Rheumatol. 1997 Dec;36(12):1290-7
references.pmid: 9448590
references.citation: Presse Med. 2013 Apr;42(4 Pt 2):534-6
references.pmid: 23453207
references.citation: Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S63-71
references.pmid: 21586199
references.citation: J Am Soc Nephrol. 2007 Jul;18(7):2180-8
references.pmid: 17582159
references.citation: Arthritis Rheum. 1995 Nov;38(11):1638-45
references.pmid: 7488285
references.citation: N Engl J Med. 2010 Jul 15;363(3):221-32
references.pmid: 20647199
references.citation: Presse Med. 2012 Oct;41(10):1024-30
references.pmid: 22906773